Apeximmune Therapeutics Inc.
South San Francisco, CA
- UEI
- LQVBQAEB9L23
- CAGE
- 8MG78
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 650 Gateway Blvd Ste 110, South San Francisco, CA 94080, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| PLA2G2D antibodies for cancer immunotherapy | National Cancer Institute (NIH) | $399,618 |
Quick answers
Is Apeximmune Therapeutics Inc. registered in SAM.gov?
Yes. Apeximmune Therapeutics Inc.'s SAM.gov registration is active through July 23, 2027.
What is Apeximmune Therapeutics Inc.'s most recent federal award?
Apeximmune Therapeutics Inc.'s most recent federal grant award is PLA2G2D antibodies for cancer immunotherapy (R43CA278134), from National Cancer Institute (NIH), on June 9, 2023.
On GovTribe
See Apeximmune Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors